Anika Therapeutics, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

Anika Therapeutics, Inc.

(Name of Registrant as Specified in its Charter) Not applicable. (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

Steve Griffin

April 28, 2026 Dear Fellow Anika Stockholder, 2025 was an important year for Anika—one in which we strengthened our foundation, advanced our innovation pipeline, and delivered solid performance across our core businesses. Throughout the year, we maintained a disciplined focus on execution, improved operational performance, and continued positioning Anika for sustainable long-term growth.

Following the portfolio actions completed at the end of 2024 and early 2025, we operated as a more focused organization centered on our hyaluronic-acid (HA)–based OA Pain Management and Regenerative Solutions businesses. This focus enabled us to direct capital, talent, and commercial resources toward the programs with the greatest return potential and the strongest alignment with our core scientific and clinical capabilities.

Our Commercial Channel, which includes both our international OA Pain Management portfolio and our Regenerative Solutions business, remained the primary engine of growth in 2025. Our OA Pain Management franchise delivered strong performance, supported by continued global demand for Monovisc and Orthovisc, as well as sustained commercial momentum for Cingal internationally. Commercial Channel revenue grew 15% year over year, and in the fourth quarter alone increased 22%, driven by strong international OA Pain Management performance and accelerating adoption of the Integrity Implant System.

Within Regenerative Solutions, surgeon adoption of the Integrity Implant System expanded significantly, with utilization and revenue more than doubling in 2025. Integrity continues to demonstrate strong clinical appeal and has rapidly become one of our most important commercial growth drivers. Hyalofast, our single-stage HA cartilage repair scaffold, also advanced meaningfully with both strong growth outside the U.S. and the completion of key regulatory milestones in the U.S. Based on the strength of the overall clinical results and supporting international data, we filed the final PMA module for Hyalofast in 2025 and, in early 2026, received FDA feedback and are preparing responses as we continue progressing toward a future U.S. launch.

Complementing the growth of our Commercial Channel, our OEM Channel—driven primarily by U.S. OA Pain Management through our long-standing partnership with J&J MedTech—remained a highly cash-generative component of our business. While OEM revenue declined due to anticipated U.S. pricing dynamics for Monovisc and Orthovisc, the strong cash contribution of this channel continues to play an important role in funding our HA-based innovation pipeline and supporting our long-term strategy to diversify a greater share of revenue toward the higher-growth Commercial Channel.

Looking ahead, our strategy is anchored in three core priorities that will guide Anika’s next phase of shareholder value creation. We are focused on accelerating growth through our Commercial Channel by building on strong international OA Pain Management momentum and scaling Integrity utilization in the U.S. We remain committed to advancing a robust HA-based product pipeline, including Hyalofast and Cingal, which represent significant opportunities in cartilage repair and next-generation OA pain management. Finally, we are strengthening operational discipline with improved productivity, rigorous cost control, and a continued emphasis on aligning resources with our highest-return programs.

We believe the significant progress made in 2025 reflects the strength of our focused strategy and positions Anika to deliver long-term value for our stockholders.

On behalf of the Board and management team, we thank you for your continued support.

Sincerely,

Steve Griffin

President and Chief Executive Officer

April 28, 2026

Dear Fellow Stockholder:

It is my pleasure to invite you to attend the Annual Meeting of Stockholders of Anika Therapeutics, Inc. (“Anika” or “Company”) to be held on June 18, 2026, at 8:30 a.m., Eastern time (“Annual Meeting”). This year’s Annual Meeting will be a “virtual meeting” conducted via live audio webcast, consistent with our recent practice. Each holder of common stock as of 5:00 p.m., Eastern time, on the record date of April 21, 2026, will be able to participate in the Annual Meeting by accessing a live webcast at www.virtualshareholdermeeting.com/ANIK2026 and entering the control number included on the holder’s Notice of Internet Availability of Proxy Materials or proxy card. Stockholders will also be able to vote their shares and submit questions via the internet during the meeting by participating in the webcast.

During the Annual Meeting stockholders will be asked (1) to elect three Class III Directors, (2) to ratify the appointment of Deloitte & Touche LLP as our independent auditor for 2026, (3) to approve, by an advisory vote, our 2025 executive compensation as disclosed in the Proxy Statement for the Annual Meeting (a “say-on-pay” vote), (4) to approve an amendment to our 2017 Omnibus Incentive Plan, and (5) to approve an amendment to our 2021 Employee Stock Purchase Plan. Each of these matters is important, and we urge you to vote in favor of the election of each of the Company’s director nominees, the ratification of the appointment of our independent auditor, the approval, on an advisory basis, of our 2025 executive compensation, and the amendments of our 2017 Omnibus Incentive Plan and our 2021 Employee Stock Purchase Plan.

We are furnishing materials to our stockholders over the internet. This process expedites the delivery of proxy materials to our stockholders, lowers our costs, and reduces the environmental impact of the Annual Meeting. Today, we are sending to each of our stockholders of record as of April 21, 2026, a Notice of Internet Availability of Proxy Materials containing instructions on how to access our Proxy Statement for the Annual Meeting and our 2025 Annual Report to Stockholders, containing financial statements for the fiscal year ended December 31, 2025, as well as instructions on how to vote via proxy either by telephone, over the internet or by mail.

It is important that you vote your shares of common stock virtually or by proxy, regardless of the number of shares you own. You will find instructions for voting on your Notice of Internet Availability of Proxy Materials and proxy card. We appreciate your prompt attention.

The Board of Directors invites you to participate in the Annual Meeting where Anika will address appropriate general questions about the business as time allows. Thank you for your support, and we look forward to joining you at the Annual Meeting.

Sincerely,

Cheryl R. Blanchard, Ph.D.

Executive Chair of the Board

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

The Board of Directors of Anika Therapeutics, Inc. (“Anika”), a Delaware corporation, is soliciting proxies for use at Anika’s 2026 Annual Meeting of Stockholders being held on June 18, 2026, at 8:30 a.m., Eastern time (“Annual Meeting”). You are receiving the enclosed Proxy Statement because you were a holder of Anika’s common stock as of 5:00 p.m., Eastern time, on the record date of April 21, 2026, and therefore are entitled to vote at the Annual Meeting. You may participate in the Annual Meeting, including casting votes and asking questions, by accessing a live webcast atvirtualshareholdermeeting.com/ANIK2026. Online check-in to the Annual Meeting will begin at 8:15 a.m., Eastern time, and stockholders are encouraged to allow ample time to log in to the meeting webcast and test their computer and audio system. There will be no physical location for the Annual Meeting.

At the Annual Meeting the following matters will be considered:

Each share of common stock is entitled to one vote for each director position and other proposal. In accordance with the rules of the Securities and Exchange Commission (“SEC”), we are providing stockholders with access to proxy materials on the internet, instead of mailing printed copies. We are mailing to stockholders of record as of April 21, 2026, commencing on or about April 28, 2026, a Notice of Internet Availability of Proxy Materials to provide:

Some stockholders will receive copies of the Proxy Statement, a proxy card and the 2025 Annual Report to Stockholders by mail or e-mail. If you received a Notice of Internet Availability of Proxy Materials by mail and would like to receive a printed copy of our proxy materials, you may request those materials by following the instructions included in the Notice of Internet Availability of Proxy Materials.

Your vote is important. Whether or not you plan to participate in the Annual Meeting, please complete and return your proxy card or vote by telephone or via the internet by following the instructions on the Notice of Internet Availability of Proxy Materials. Returning a proxy card or otherwise submitting your proxy does not deprive you of your right to access the Annual Meeting and vote during the webcast at that time.

Anika will maintain a list of stockholders of record as of the record date at Anika’s corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts, for a period beginning ten days prior to the Annual Meeting and ending at the close of the Annual Meeting. A list of stockholders of record as of the record date will be made available to stockholders during the Annual Meeting atwww.virtualshareholdermeeting.com/ANIK2026.

By Order of the Board of Directors,

David B. Colleran

Executive Vice President, General Counsel and Secretary

Bedford, Massachusetts

April 28, 2026

Important Notice Regarding Availability of Proxy Materials for Annual Meeting on June 18, 2026:

The Notice of Annual Meeting of Stockholders, Proxy Statement and 2025 Annual Report to Stockholders are

available atwww.proxyvote.com.

32 Wiggins Avenue

Bedford, Massachusetts 01730

Proxy Statement dated April 28, 2026

2026 Annual Meeting of Stockholders

Anika Therapeutics, Inc., a Delaware corporation, is furnishing this Proxy Statement and the related proxy materials in connection with the solicitation by its Board of Directors of proxies to be voted at its 2026 Annual Meeting of Stockholders and any postponements or adjournments thereof. Anika Therapeutics, Inc. is providing these materials to the holders of record of its common stock as of the close of business on April 21, 2026, and is first making available or mailing the materials on or about April 28, 2026.

The Annual Meeting is scheduled to be held as follows:

Meeting Webcast Address: www.virtualshareholdermeeting.com/ANIK2026

Your vote is important.

Please see the detailed information that follows.

Table of Contents